article thumbnail

Opinion: Policymakers must take action on the physician shortage

STAT

These workforce challenges are compounded by the fact that America — both physicians  and our patient population — is also aging, and the number of available doctors is shrinking. Nearly 334,000  health care professionals left the workforce in 2021.

article thumbnail

Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’

pharmaphorum

That spend is due to reach of $3 billion by 2025, according to GlobalData analyst Kitty Whitney, who notes that there has been a steady stream of startups formed in the last three to four years to tap into the emerging AI market. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First-in-class drug slows tumor growth in preclinical study - set for clinic by 2025

Outsourcing Pharma

A small molecule compound has shown to induce strong anti-tumor immune responses â an area where medical need is high.

article thumbnail

Gout market across 7MM set to reach $10.8 bn in 2032 fueled by novel ULTs and rising prevalence: GlobalData

Express Pharma

The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual growth rate (CAGR) of 8.8 per cent from $4.6 billion in 2022 to $10.8 billion in 2032, in line with the steadily increasing disease prevalence and the entrance of novel agents, according to GlobalData.

article thumbnail

Sanofi to focus on 12 blockbuster drug candidates, immunology pipeline

Express Pharma

Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while boosting research and development spending. The 12 blockbuster drugs include nine medicines and vaccines with 2 billion to 5 euros ($2.15-$5.38

article thumbnail

Diving deeper into AI discovery, Sanofi signs 5-drug deal with Atomwise

pharmaphorum

The deal will see Atomwise identify, synthesize, and advance lead compounds for up to five drug targets that will then be exclusively Sanofi’s to develop. A recent report from GlobalData predicted that pharma spending on AI drug discovery would hit $3 billion in 2025.

article thumbnail

Novel therapies to drive Crohn’s disease market growth across 8MM to $15 bn by 2032: GlobalData

Express Pharma

Against this backdrop, the CD drug sales across the eight-major markets (8MM*) are set to increase at a compound annual growth rate (CAGR) of 4.7 The anticipated launches in the US and Europe of Janssen’s Tremfya (guselkumab) and Lilly’s mirikizumab, in Q4 2025 and Q3 2026, respectively, are expected to shape the market.